Media & Interviews
Working with journalists, editors and event organizers.
Approved topics, short and long biographies, suggested interview questions and direct contact for professional media inquiries.
Short biography (approximately 100 words)
Marcela Riaño Caro is a Molecular Diagnostics and Laboratory Strategy Leader with more than fifteen years of international experience across in vitro diagnostics at Abbott Laboratories, DiaSorin and Roche Diagnostics in Canada and Latin America. She is a bacteriologist and clinical microbiologist trained at Pontificia Universidad Javeriana with graduate work in molecular biology.
Long biography
Marcela Riaño Caro is a Molecular Diagnostics and Laboratory Strategy Leader whose work spans peer-reviewed molecular virology research, in vitro diagnostics product leadership, and clinical laboratory transformation across Latin America and Canada.
Her scientific record includes peer-reviewed publications on rotavirus, adenovirus and viral diversity in pediatric acute diarrhea (MEDICAS UIS, 2000; Revista Latinoamericana de Microbiología, 2006), and an author-attributed Rotavirus C VP7 sequence in NCBI GenBank (CAD70160.1) deposited via a collaboration with the Viral Gastroenteritis Section of the U.S. Centers for Disease Control and Prevention.
Her diagnostics leadership includes consultative laboratory work with Canadian national laboratory networks at Abbott Laboratories (2023–2026); regional marketing leadership for immunology and molecular portfolios across 12 Latin American markets at DiaSorin (2020–2023), including integration of Luminex molecular solutions; and more than a decade at Roche Diagnostics in Colombia and the wider LATAM region, spanning centralized laboratory solutions product management (including e801 and t511 launches), scientific and commercial training of hundreds of regional stakeholders, and field application support for molecular and sequencing platforms.
She is based in Ontario, Canada, and works in English and Spanish.
Approved professional topics
- AI and predictive diagnostics in clinical laboratories
- Laboratory automation and workflow transformation
- Development and expansion of molecular diagnostic services
- Health technology adoption in regulated markets
- Diagnostic portfolio strategy for in vitro diagnostics
- Scientific commercialization and market development
- LATAM and Canadian diagnostics ecosystems
Suggested interview questions
- Where can artificial intelligence genuinely add value in clinical laboratories today?
- What is the difference between a research-grade AI tool and a diagnostic tool a clinical laboratory can safely deploy?
- How do you develop a new molecular diagnostic service in a hospital laboratory?
- Why do technically excellent diagnostic technologies sometimes fail to reach patients?
- How does health technology adoption differ between Latin American and Canadian markets?
- What are the most important guardrails for AI in molecular diagnostics?
- How should a laboratory director build a business case for a new diagnostic technology?
Interviews & features
Interviews and features coming soon.
Verified interviews, features and speaking appearances will be listed here as they are published. No placeholder logos or fictional media appearances are shown on this page.
Media and interview requests
For interview, podcast, speaking or expert-commentary requests, please write to Marcela directly. Response times are typically within a few business days.
The content of this website and any interview or commentary provided by Marcela Riaño Caro is informational and does not constitute medical advice, diagnosis or treatment. Marcela is not a physician or clinician. Interview quotes should be reviewed with Marcela before publication.